TradingKey – As Capital Markets Day approaches, Novo Nordisk (NVO) is facing increasingly evident pressure from institutional investors.

On September 21 local time, the Danish drugmaker will hold its Capital Markets Day in London to officially outline its new corporate strategy. This will also mark the first comprehensive presentation of the company’s future direction to investors by newly appointed CEO Mike Doustdar.

Over the past few years, products like Ozempic and Wegovy propelled Novo Nordisk into a key player in the global weight-loss drug market, with its market capitalization once surpassing $600 billion. However, as Eli Lilly (LLY) continues to capture market share with Zepbound, Novo Nordisk’s competitive edge in key markets…